Algert Global LLC Purchases 36,590 Shares of Arcus Biosciences, Inc. (NYSE:RCUS)

Algert Global LLC raised its position in shares of Arcus Biosciences, Inc. (NYSE:RCUS) by 48.0% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 112,847 shares of the company’s stock after purchasing an additional 36,590 shares during the period. Algert Global LLC owned about 0.12% of Arcus Biosciences worth $1,725,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also made changes to their positions in the company. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its holdings in shares of Arcus Biosciences by 25.1% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 931,048 shares of the company’s stock valued at $14,236,000 after acquiring an additional 186,750 shares in the last quarter. SG Americas Securities LLC increased its position in Arcus Biosciences by 1,396.1% during the 2nd quarter. SG Americas Securities LLC now owns 129,292 shares of the company’s stock valued at $1,969,000 after purchasing an additional 120,650 shares during the period. Vanguard Group Inc. raised its holdings in shares of Arcus Biosciences by 2.4% in the 1st quarter. Vanguard Group Inc. now owns 4,791,244 shares of the company’s stock valued at $90,459,000 after purchasing an additional 110,528 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new stake in shares of Arcus Biosciences in the 2nd quarter worth approximately $1,286,000. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of Arcus Biosciences by 11.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 566,979 shares of the company’s stock valued at $8,669,000 after purchasing an additional 59,536 shares in the last quarter. 92.89% of the stock is currently owned by hedge funds and other institutional investors.

Arcus Biosciences Trading Up 0.1 %

Shares of NYSE:RCUS opened at $15.80 on Thursday. The company has a current ratio of 5.24, a quick ratio of 5.24 and a debt-to-equity ratio of 0.08. Arcus Biosciences, Inc. has a 12-month low of $13.52 and a 12-month high of $20.31. The business has a 50 day moving average of $16.30 and a two-hundred day moving average of $16.05. The company has a market capitalization of $1.45 billion, a PE ratio of -5.02 and a beta of 0.89.

Arcus Biosciences (NYSE:RCUS) last posted its earnings results on Wednesday, November 6th. The company reported ($1.00) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.06) by $0.06. Arcus Biosciences had a negative net margin of 102.66% and a negative return on equity of 45.59%. The firm had revenue of $48.00 million during the quarter, compared to analysts’ expectations of $38.95 million. During the same period in the previous year, the business posted ($0.94) EPS. The business’s revenue was up 50.0% compared to the same quarter last year. As a group, analysts forecast that Arcus Biosciences, Inc. will post -3.2 EPS for the current year.

Wall Street Analysts Forecast Growth

RCUS has been the subject of a number of recent research reports. Wedbush reissued an “outperform” rating and issued a $36.00 price objective on shares of Arcus Biosciences in a research note on Thursday, November 7th. Wells Fargo & Company initiated coverage on Arcus Biosciences in a research note on Tuesday, October 8th. They set an “overweight” rating and a $29.00 price objective for the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arcus Biosciences in a research note on Thursday, October 3rd. HC Wainwright reissued a “neutral” rating and set a $20.00 price target on shares of Arcus Biosciences in a research report on Wednesday, November 6th. Finally, Barclays raised their price target on shares of Arcus Biosciences from $25.00 to $29.00 and gave the company an “overweight” rating in a report on Friday, October 25th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $34.00.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.